Alesion
PreclinicalSmall molecule
Boehringer IngelheimAlesion is one of 80 small molecule programs targeting Urticaria. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Asmanex Hfa
PPerrigo Company
Phase 3
Sudafed
KKenvue Brands
Phase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Kenalog
BBassett Healthcare
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Active Comparator
ModernaPhase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
Allegra-D
PfizerPhase 3
Asmanex
NovartisPreclinical
Ismigen
LLallemand Pharma AG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alesion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company